{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:46:09Z","timestamp":1792773969646,"version":"4.5.0"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Non-conventional prostate cancer histologies represent a small but clinically significant subset characterized by aggressive behavior, atypical biomarker profiles, and reduced dependence on androgen receptor signaling. Evidence indicates these histologies reflect dynamic biological states driven by genomic instability, lineage plasticity, and therapeutic selection rather than static morphologic entities, with several morphologies acting as accessible, if imperfect, surrogates for actionable alterations. We performed a translational narrative review integrating anatomic pathology, genomic and epigenomic biology, and biomarker-selected therapy, searching PubMed\/MEDLINE, Embase, Cochrane CENTRAL, the ASCO Meeting Library, ESMO publications, and APCCC through May 2026, spanning neuroendocrine, ductal, intraductal, cribriform, adenosquamous, sarcomatoid, adenoid cystic, signet ring cell, and mucinous subtypes. These histologies are individually uncommon but are consistently associated with advanced stage and inferior survival. Neuroendocrine prostate cancer is the most aggressive phenotype and a major mechanism of resistance to AR-directed therapy, driven by combined RB1 and TP53 loss, epigenetic reprogramming, and lineage plasticity, and marked by DLL3 expression. Cribriform and intraductal carcinoma are often enriched for BRCA2 and DNA-repair deficiency, whereas ductal differentiation is associated with mismatch-repair deficiency in a subset, with implications for PARP inhibition and checkpoint blockade. Emerging strategies include platinum-based chemoimmunotherapy and investigational lineage-directed agents targeting DLL3, STEAP1, KLK2, and TROP-2, alongside radioligands. These histologies are best viewed as biologically distinct, evolving disease states. By integrating pathology, molecular biology, and biomarker-selected therapy into one translational pathway, this review reframes non-conventional histology as a prompt for early molecular characterization and adaptive, biology-driven treatment.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag391","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:45:22Z","timestamp":1790855122000},"source":"Crossref","is-referenced-by-count":0,"title":["Non-conventional histologies of prostate cancer: from morphology to biology-driven precision oncology"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5699-4958","authenticated-orcid":false,"given":"Fabiano","family":"Flauto","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University , Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2412-1310","authenticated-orcid":false,"given":"Giuseppe","family":"Neola","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University , Naples, 80131,","place":["Italy"]},{"name":"Portsmouth Hospitals University NHS Trust , Portsmouth, PO6 3LY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-3514","authenticated-orcid":false,"given":"Alessia","family":"Cimadamore","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institute of Pathological Anatomy, University of Udine , Udine, 33100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7877-8988","authenticated-orcid":false,"given":"Michele","family":"Maffezzoli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University Hospital of Parma-Medical Oncology Unit, University of Parma , Parma, 43126,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-0105","authenticated-orcid":false,"given":"Akash","family":"Maniam","sequence":"additional","affiliation":[{"name":"Portsmouth Hospitals University NHS Trust , Portsmouth, PO6 3LY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5814-2296","authenticated-orcid":false,"given":"Sarah","family":"Scagliarini","sequence":"additional","affiliation":[{"name":"UOC di Oncologia, Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli , Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7863-3540","authenticated-orcid":false,"given":"Fabio","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"Medical Oncology 1, IRCCS Regina Elena National Cancer Institute , Rome, 00128,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7205-5105","authenticated-orcid":false,"given":"Luigi","family":"Formisano","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University , Naples, 80131,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4668-4765","authenticated-orcid":false,"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[{"name":"Translational & Clinical Research Institute, Centre for Cancer, Newcastle University , Newcastle Upon Tyne, NE2 4HH,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-3650","authenticated-orcid":false,"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[{"name":"Portsmouth Hospitals University NHS Trust , Portsmouth, PO6 3LY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026102312364942000_oyag391-B1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2014part B: prostate and urinary tract tumours","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"2026102312364942000_oyag391-B2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/pcan.2012.4","article-title":"A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008","volume":"15","author":"Marcus","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026102312364942000_oyag391-B3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/JU.0000000000001011","article-title":"Rare histological variants of prostate adenocarcinoma: a National Cancer Database analysis","volume":"204","author":"Bronkema","year":"2020","journal-title":"J Urol"},{"key":"2026102312364942000_oyag391-B4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"2026102312364942000_oyag391-B5","article-title":"Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations","volume":"3","author":"Schweizer","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"2026102312364942000_oyag391-B6","author":"American Joint Committee on Cancer","year":"2017","journal-title":"AJCC Cancer Staging Manual"},{"key":"2026102312364942000_oyag391-B7","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of Prostatic Carcinoma","volume":"44","author":"Van Leenders","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"2026102312364942000_oyag391-B8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.eururo.2017.03.013","article-title":"Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories","volume":"72","author":"Porter","year":"2017","journal-title":"Eur Urol"},{"key":"2026102312364942000_oyag391-B9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.euo.2025.05.001","article-title":"Assessment of the reporting and incidence of Prostate Cancer unconventional histologies in tertiary referral institutions: An under-reported but exploding phenomenon?","volume":"8","author":"Marra","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"2026102312364942000_oyag391-B10","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/PAS.0000000000000238","article-title":"Best practices recommendations in the application of immunohistochemistry in the prostate","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"2026102312364942000_oyag391-B11","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3390\/curroncol29030152","article-title":"Adenoid cystic carcinoma\/basal cell carcinoma of the prostate: overview and update on rare prostate cancer subtypes","volume":"29","author":"Cozzi","year":"2022","journal-title":"Curr Oncol"},{"key":"2026102312364942000_oyag391-B12","doi-asserted-by":"crossref","first-page":"eaav0891","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026102312364942000_oyag391-B13","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1470-2045(24)00249-3","article-title":"Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1\/2, first-in-human trial","volume":"25","author":"Tendler","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026102312364942000_oyag391-B14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"2026102312364942000_oyag391-B15","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026102312364942000_oyag391-B16","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1093\/annonc\/mdv356","article-title":"High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers","volume":"26","author":"Castro","year":"2015","journal-title":"Ann Oncol"},{"key":"2026102312364942000_oyag391-B17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2021.01.027","article-title":"Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer","volume":"147","author":"Lozano","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026102312364942000_oyag391-B18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2023.02.022","article-title":"Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers","volume":"185","author":"Lozano","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026102312364942000_oyag391-B19","doi-asserted-by":"crossref","first-page":"82504","DOI":"10.18632\/oncotarget.12697","article-title":"Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate","volume":"7","author":"Schweizer","year":"2016","journal-title":"Oncotarget"},{"key":"2026102312364942000_oyag391-B20","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-17-0955","article-title":"MSH2 loss in primary prostate cancer","volume":"23","author":"Guedes","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026102312364942000_oyag391-B21","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0090-4295(98)00418-X","article-title":"Adenosquamous carcinoma of the prostate: case report with DNA analysis, immunohistochemistry, and literature review","volume":"53","author":"Bassler","year":"1999","journal-title":"Urology"},{"key":"2026102312364942000_oyag391-B22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12920-021-01068-w","article-title":"Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report","volume":"14","author":"Kitamura","year":"2021","journal-title":"BMC Med Genomics"},{"key":"2026102312364942000_oyag391-B23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12894-025-01790-y","article-title":"Sarcomatoid prostate carcinoma: a case report","volume":"25","author":"Hafiani","year":"2025","journal-title":"BMC Urol"},{"key":"2026102312364942000_oyag391-B24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3390\/jcm7080218","article-title":"Primary signet ring cell carcinoma of the prostate: a rare case report","volume":"7","author":"G\u00f6k","year":"2018","journal-title":"J Clin Med"},{"key":"2026102312364942000_oyag391-B25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4103\/jcrt.jcrt_827_21","article-title":"Primary signet ring cell carcinoma of prostate: a rare case report and review of literature","volume":"19","author":"Gupta","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"2026102312364942000_oyag391-B26","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1038\/modpathol.2017.132","article-title":"Mucinous and secondary tumors of the prostate","volume":"31","author":"Osunkoya","year":"2018","journal-title":"Mod Pathol"},{"key":"2026102312364942000_oyag391-B27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.annonc.2026.01.015","article-title":"Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"key":"2026102312364942000_oyag391-B28","author":"National Comprehensive Cancer Network (NCCN)","year":"2025"},{"key":"2026102312364942000_oyag391-B29","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026102312364942000_oyag391-B30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026102312364942000_oyag391-B31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41698-021-00211-1","article-title":"Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis","volume":"5","author":"Conteduca","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2026102312364942000_oyag391-B32","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1172\/JCI131041","article-title":"Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer","volume":"130","author":"Beltran","year":"2020","journal-title":"J Clin Invest"},{"key":"2026102312364942000_oyag391-B33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and biological features of neuroendocrine prostate cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr Oncol Rep."},{"key":"2026102312364942000_oyag391-B34","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","article-title":"Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy","volume":"81","author":"Cheng","year":"2022","journal-title":"Eur Urol"},{"key":"2026102312364942000_oyag391-B35","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","article-title":"The DNA methylation landscape of advanced prostate cancer","volume":"52","author":"Zhao","year":"2020","journal-title":"Nat Genet."},{"key":"2026102312364942000_oyag391-B36","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nm.4341","article-title":"Biology and evolution of poorly differentiated neuroendocrine tumors","volume":"23","author":"Rickman","year":"2017","journal-title":"Nat Med."},{"key":"2026102312364942000_oyag391-B37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"2026102312364942000_oyag391-B38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"2026102312364942000_oyag391-B39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"key":"2026102312364942000_oyag391-B40","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","article-title":"An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer","volume":"23","author":"Davies","year":"2021","journal-title":"Nat Cell Biol."},{"key":"2026102312364942000_oyag391-B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-69308-0","article-title":"Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity","volume":"17","author":"Singh","year":"2026","journal-title":"Nat Commun."},{"key":"2026102312364942000_oyag391-B42","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1038\/s41467-021-26042-z","article-title":"Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer","volume":"12","author":"Cejas","year":"2021","journal-title":"Nat Commun."},{"key":"2026102312364942000_oyag391-B43","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"key":"2026102312364942000_oyag391-B44","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J Clin Invest."},{"key":"2026102312364942000_oyag391-B45","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.euo.2026.01.011","article-title":"Prognosis and treatment response in aggressive-variant prostate cancer and treatment-related neuroendocrine prostate cancer: a systematic review and meta-analysis","volume":"9","author":"Pedrani","year":"2026","journal-title":"Eur Urol Oncol."},{"key":"2026102312364942000_oyag391-B46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.euros.2024.10.008","article-title":"Prognostic expression signature of RB1, PTEN, and TP53 genes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor pathway inhibitors","volume":"70","author":"Garcia de Herreros","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"2026102312364942000_oyag391-B47","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res."},{"key":"2026102312364942000_oyag391-B48","doi-asserted-by":"crossref","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med."},{"key":"2026102312364942000_oyag391-B49","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1158\/0008-5472.CAN-17-0299","article-title":"Noninvasive interrogation of DLL3 expression in metastatic small cell lung cancer","volume":"77","author":"Sharma","year":"2017","journal-title":"Cancer Res."},{"key":"2026102312364942000_oyag391-B50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol Oncol."},{"key":"2026102312364942000_oyag391-B51","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1073\/pnas.1905384117","article-title":"Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1","volume":"117","author":"Hsu","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2026102312364942000_oyag391-B52","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1158\/1078-0432.CCR-22-1305","article-title":"Expression and therapeutic targeting of TROP-2 in treatment-resistant prostate cancer","volume":"29","author":"Sperger","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2026102312364942000_oyag391-B53","first-page":"73","article-title":"The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target","volume":"9","author":"Shen","year":"2021","journal-title":"Am J Clin Exp Urol"},{"key":"2026102312364942000_oyag391-B54","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.urolonc.2026.111032","article-title":"Cell-surface targets for prostate cancer therapeutics","volume":"44","author":"Ruder","year":"2026","journal-title":"Urol Oncol."},{"key":"2026102312364942000_oyag391-B55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13550-026-01396-x","article-title":"Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting","volume":"16","author":"Harbi","year":"2026","journal-title":"EJNMMI Res."},{"key":"2026102312364942000_oyag391-B56","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1097\/PAP.0000000000000522","article-title":"Ductal adenocarcinoma of the prostate: evolution and current state","volume":"33","author":"Cimadamore","year":"2026","journal-title":"Adv Anat Pathol."},{"key":"2026102312364942000_oyag391-B57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/bco2.60","article-title":"Ductal adenocarcinoma of the prostate: a systematic review and meta-analysis of incidence, presentation, prognosis, and management","volume":"2","author":"Ranasinha","year":"2021","journal-title":"BJUI Compass."},{"key":"2026102312364942000_oyag391-B58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.015","article-title":"Genetic profile of ductal adenocarcinoma of the prostate","volume":"69","author":"Seipel","year":"2017","journal-title":"Hum Pathol."},{"key":"2026102312364942000_oyag391-B59","doi-asserted-by":"crossref","first-page":"13671","DOI":"10.1038\/ncomms13671","article-title":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","volume":"8","author":"Taylor","year":"2017","journal-title":"Nat Commun."},{"key":"2026102312364942000_oyag391-B60","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4274\/uob.galenos.2026.2025.12.1","article-title":"Prognostic impact of intraductal carcinoma in patients with metastatic prostate cancer treated with abiraterone acetate or enzalutamide","volume":"25","author":"B\u00f6lek","year":"2026","journal-title":"Bull Urooncol"},{"key":"2026102312364942000_oyag391-B61","doi-asserted-by":"publisher","first-page":"55374","DOI":"10.18632\/oncotarget.19520","article-title":"The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget."},{"key":"2026102312364942000_oyag391-B62","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med."},{"key":"2026102312364942000_oyag391-B63","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol."},{"key":"2026102312364942000_oyag391-B64","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","article-title":"Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations","volume":"75","author":"Antonarakis","year":"2019","journal-title":"Eur Urol."},{"key":"2026102312364942000_oyag391-B65","doi-asserted-by":"crossref","first-page":"e0233260","DOI":"10.1371\/journal.pone.0233260","article-title":"Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies","volume":"15","author":"Graham","year":"2020","journal-title":"PLoS One"},{"key":"2026102312364942000_oyag391-B66","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pros.23484","article-title":"Intraductal\/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","volume":"78","author":"Isaacsson Velho","year":"2018","journal-title":"Prostate."},{"key":"2026102312364942000_oyag391-B67","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2018.01.035","article-title":"Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide","volume":"74","author":"Antonarakis","year":"2018","journal-title":"Eur Urol."},{"key":"2026102312364942000_oyag391-B68","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/s41379-019-0297-6","article-title":"MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia","volume":"32","author":"Magers","year":"2019","journal-title":"Mod Pathol."},{"key":"2026102312364942000_oyag391-B69","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.humpath.2015.05.002","article-title":"A subset of prostatic basal cell carcinomas harbor the MYB rearrangement of adenoid cystic carcinoma","volume":"46","author":"Bishop","year":"2015","journal-title":"Hum Pathol."},{"key":"2026102312364942000_oyag391-B70","doi-asserted-by":"crossref","first-page":"102281","DOI":"10.1016\/j.clgc.2024.102281","article-title":"Eighty-nine cases of primary prostatic signet ring cell carcinoma\u2014systematic review","volume":"23","author":"Boot","year":"2025","journal-title":"Clin Genitourin Cancer."},{"key":"2026102312364942000_oyag391-B71","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41388-022-02350-6","article-title":"Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets","volume":"41","author":"Puccini","year":"2022","journal-title":"Oncogene."},{"key":"2026102312364942000_oyag391-B72","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4065\/mcp.2010.0463","article-title":"Primary signet ring cell carcinoma of the prostate","volume":"85","author":"Warner","year":"2010","journal-title":"Mayo Clin Proc."},{"key":"2026102312364942000_oyag391-B73","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/PAS.0b013e3181589f72","article-title":"Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases","volume":"32","author":"Osunkoya","year":"2008","journal-title":"Am J Surg Pathol."},{"key":"2026102312364942000_oyag391-B74","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2017.71","article-title":"Unravelling the biology of SCLC: implications for therapy","volume":"14","author":"Sabari","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2026102312364942000_oyag391-B75","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/annonc\/mdn694","article-title":"Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features","volume":"20","author":"Loriot","year":"2009","journal-title":"Ann Oncol."},{"key":"2026102312364942000_oyag391-B76","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol."},{"key":"2026102312364942000_oyag391-B77","doi-asserted-by":"crossref","first-page":"102172","DOI":"10.1016\/j.clgc.2024.102172","article-title":"The use of lurbinectedin for the treatment of small-cell and neuroendocrine carcinoma of the prostate","volume":"22","author":"Meyer","year":"2024","journal-title":"Clin Genitourin Cancer."},{"issue":"16 suppl","key":"2026102312364942000_oyag391-B78","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1200\/JCO.2026.44.16_suppl.5016","article-title":"Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive-variant metastatic prostate cancer (CHAMP)","volume":"44","author":"Armstrong","year":"2026","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"2026102312364942000_oyag391-B79","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1200\/JCO.2025.43.16_suppl.5008","article-title":"C3NIRA: randomized phase II study of carboplatin-cabazitaxel-cetrelimab (anti-PD-1) induction followed by niraparib\u2009\u00b1\u2009cetrelimab maintenance in men with aggressive-variant prostate cancers (AVPC)","volume":"43","author":"Aparicio","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026102312364942000_oyag391-B80","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study","volume":"31","author":"Aggarwal","year":"2025","journal-title":"Clin Cancer Res."},{"key":"2026102312364942000_oyag391-B81","first-page":"22","article-title":"BiTE: teaching antibodies to engage T-cells for cancer therapy","volume":"11","author":"Baeuerle","year":"2009","journal-title":"Curr Opin Mol Ther."},{"key":"2026102312364942000_oyag391-B82","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med."},{"key":"2026102312364942000_oyag391-B83","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1158\/1535-7163.MCT-25-0453","article-title":"Preclinical activity of the DLL3-targeted T-cell engager MK-6070 in neuroendocrine prostate cancer","volume":"25","author":"Ku","year":"2026","journal-title":"Mol Cancer Ther."},{"key":"2026102312364942000_oyag391-B84","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2\u2009+\u20091 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov."},{"key":"2026102312364942000_oyag391-B85","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: a phase I study","volume":"43","author":"Stein","year":"2025","journal-title":"J Clin Oncol."},{"key":"2026102312364942000_oyag391-B86","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A phase II trial of the Aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res."},{"key":"2026102312364942000_oyag391-B87","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/acs.jmedchem.4c02768","article-title":"PSMA and SSTR2 dual-targeting theranostic agents for neuroendocrine-differentiated prostate cancer (NEPC)","volume":"68","author":"Jin","year":"2025","journal-title":"J Med Chem."},{"key":"2026102312364942000_oyag391-B88","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-23-0536","article-title":"Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: a phase I clinical trial","volume":"29","author":"Abel","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2026102312364942000_oyag391-B89","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/pros.24292","article-title":"DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy","volume":"82","author":"Zhu","year":"2022","journal-title":"Prostate."},{"key":"2026102312364942000_oyag391-B90","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.urology.2021.05.028","article-title":"Cribriform prostate cancer: clinical pathologic and molecular considerations","volume":"155","author":"Hesterberg","year":"2021","journal-title":"Urology."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag391\/71605191\/oyag391.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag391\/71605191\/oyag391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag391\/71605191\/oyag391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:36:59Z","timestamp":1792773419000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag391\/8865133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":90,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag391","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,5]]},"article-number":"oyag391"}}